BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 226 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $2,769,000 | -35.9% | 23,350 | -25.5% | 0.03% | -22.5% |
Q4 2021 | $4,318,000 | -93.4% | 31,336 | -93.4% | 0.04% | -93.7% |
Q3 2021 | $65,771,000 | +23.7% | 473,478 | -13.6% | 0.63% | +33.8% |
Q2 2021 | $53,178,000 | +33.4% | 547,777 | -6.1% | 0.47% | +28.1% |
Q1 2021 | $39,873,000 | -29.2% | 583,367 | -11.3% | 0.37% | -29.1% |
Q4 2020 | $56,344,000 | +17.6% | 657,380 | -10.8% | 0.52% | -0.9% |
Q3 2020 | $47,912,000 | -38.9% | 736,989 | -31.2% | 0.53% | -44.9% |
Q2 2020 | $78,364,000 | +117.3% | 1,071,866 | +1.1% | 0.96% | +57.5% |
Q1 2020 | $36,068,000 | -41.9% | 1,059,893 | -7.0% | 0.61% | -29.7% |
Q4 2019 | $62,067,000 | +30.4% | 1,140,101 | -0.1% | 0.86% | +20.4% |
Q3 2019 | $47,613,000 | +1796.9% | 1,141,243 | +1891.3% | 0.72% | +309.7% |
Q2 2019 | $2,510,000 | – | 57,312 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |